2024
Analysis of drug–drug interactions in patients with HIV and metabolic syndrome
Tuan J, Igiraneza G, Ogbuagu O. Analysis of drug–drug interactions in patients with HIV and metabolic syndrome. Expert Opinion On Drug Metabolism & Toxicology 2024, 20: 953-965. PMID: 39230187, DOI: 10.1080/17425255.2024.2401044.Peer-Reviewed Original ResearchDrug-drug interactionsAntiretroviral therapyMetabolic disordersMetabolic syndromeNanotechnology-based drug delivery platformsPrevalence of metabolic comorbiditiesSelection of antiretroviral therapyLong-acting antiretroviral therapyContemporary antiretroviral therapyEffective antiretroviral therapyPrevalence of metabolic disordersRepertoire of treatment optionsDrug-drug interaction dataTreat metabolic syndromeMetabolic comorbiditiesTreatment optionsDrug delivery platformPrescribing informationAnalysis of drug-drug interactionsHIVInjectable medicationsDrug prescribing informationWeight lossPWHSyndrome
2023
Lenacapavir: a twice-yearly treatment for adults with multidrug-resistant HIV infection and limited treatment options
Tuan J, Ogbuagu O. Lenacapavir: a twice-yearly treatment for adults with multidrug-resistant HIV infection and limited treatment options. Expert Review Of Anti-infective Therapy 2023, 21: 565-570. PMID: 37067160, DOI: 10.1080/14787210.2023.2203913.Peer-Reviewed Original ResearchConceptsTreatment optionsMultidrug-resistant HIV infectionMultidrug-resistant HIVTreatment-emergent resistanceLimited treatment optionsClinical trial dataDrug-drug interactionsBreakthrough therapy designationHIV-1 capsid inhibitorsMechanism of actionAdherence supportCompanion drugsAntiretroviral agentsHIV infectionHIV treatmentClinical trialsLenacapavirPharmacodynamic propertiesDrug AdministrationExpert opinion sectionCapsid inhibitorsTrial dataU.S. FoodClinical usesYearly treatment
2018
Dolutegravir/rilpivirine for the treatment of HIV-1 infection
Dowers E, Zamora F, Barakat LA, Ogbuagu O. Dolutegravir/rilpivirine for the treatment of HIV-1 infection. HIV/AIDS - Research And Palliative Care 2018, 10: 215-224. PMID: 30464642, PMCID: PMC6220428, DOI: 10.2147/hiv.s157855.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsHIV-1 infectionDolutegravir/rilpivirineAntiretroviral therapyImportant drug-drug interactionsClinical trial efficacyDrug-drug interactionsImproved safety profileLong-term toxicityDrug package insertsRegimen simplificationMaintenance therapyCombination regimensMedication adherenceSafety profileSafety dataTrial efficacyConference abstractsPackage insertsDrug AdministrationUS FoodPharmacokinetic propertiesGoogle ScholarInfectionLimited dataRilpivirine